Investors: Press Releases

Press Releases

November 14, 2022
NexImmune Reports Third Quarter 2022 Financial Results and Announces Strategic Update
October 6, 2022
NexImmune Announces Research Collaboration with National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH)
September 9, 2022
NexImmune to Present at the H.C. Wainwright 24th Annual Global Investment Conference
August 15, 2022
NexImmune Reports Second Quarter 2022 Financial Results and Highlights FDA Clearance of IND for NEXI-003 for the Treatment of HPV-Related Cancers
July 14, 2022
NexImmune Announces IND Clearance by the US FDA for NEXI-003 for the Treatment of HPV-Related Cancers
May 12, 2022
NexImmune Reports First Quarter 2022 Financial Results and Provides Business Updates
May 10, 2022
NexImmune, Yale, and JDRF Enter into Research Partnership for Type 1 Diabetes
May 10, 2022
NexImmune Announces Appointment of Dr. Leena Gandhi to its Board of Directors
April 26, 2022
NexImmune Announces Preclinical Research Collaboration with Columbia University Irving Medical Center’s Herbert Irving Comprehensive Cancer Center
April 14, 2022
NexImmune Promotes Mathias Oelke, Ph.D., To Chief Scientific Officer
Displaying 1 - 10 of 59